Watertown, United States
Corner Therapeutics, founded in 2020, is positioned at the forefront of biotechnology innovation. Their slogan, "Generating Immunity for Life," encapsulates their mission to revolutionize the field of immunotherapy.
Specializing in the convergence of Biotechnology, Health Care, and Life Sciences, Corner Therapeutics boasts a cutting-edge dendritic cell hyperactivation (hDC) platform. This platform sets itself apart by its capacity to tackle a broad spectrum of cancers and infectious diseases, fostering robust and enduring immunity through exceptional memory T cell responses.
The company, headquartered in the United States, has already made significant strides in changing the standard of patient care, promising more effective, patient-friendly, and cost-efficient immunotherapy solutions, even for challenging conditions.
Recently, Corner Therapeutics secured a $54.00M Series A investment on 18 April 2024, with backing from Tanis Ventures, Ziff Capital Partners, and Sandia Holdings, augmenting their capability to continue their transformative work.
